By the end of this chapter you can explain what a vaccine made of mRNA actually contains.
mRNA as a set of instructions
Messenger RNA is the working copy a cell makes of a gene before it builds a protein. A vaccine built on mRNA carries one such instruction: the sequence for a single viral protein, not the virus.[1] The cell reads it, builds that protein, shows it to the immune system, and then discards the message.
The instruction is deliberately short lived. Cellular enzymes break mRNA down within hours to days, which is why the vaccine cannot keep producing protein indefinitely and why it never enters the nucleus where DNA is kept.[2]
Strong evidence
Four independent reviews agree on the degradation timeline. No source in this course contests it.
By the end of this chapter you can explain why the mRNA needs a fatty shell to survive the trip.
Lipid nanoparticle delivery
Naked mRNA is unstable in the body. Ribonucleases in the bloodstream degrade unprotected mRNA within minutes, which makes direct injection useless for most therapies.[1] The answer is encapsulation in lipid nanoparticles: spheres roughly 80 to 100nm across, built from ionizable lipids, helper lipids, cholesterol, and PEG lipid conjugates.[2]
Cells take these particles up by endocytosis. Inside the acidic endosome the ionizable lipid picks up a positive charge, destabilizes the surrounding membrane, and releases the mRNA into the cytoplasm where ribosomes can read it.[1][3]
Strong evidence
Endosomal escape confirmed across three independent cryo-EM studies between 2019 and 2021, with consistent results.
The formulation is fragile. BNT162b2 originally shipped at -70°C, and reformulation later allowed ordinary refrigeration for shorter windows.[4]
Sources disagree
Two sources report stability at 2 to 8°C for ten weeks. One FDA review notes that figure rests on a single lot study, so treat it as provisional.
By the end of this chapter you can describe what the immune system does with the protein the cell just built.
How the immune system responds
Cells that translate the vaccine mRNA display fragments of the resulting spike protein on their surface. Helper T cells recognise those fragments, and B cells that bind the same shape are selected and begin producing antibodies.[3]
The second dose matters because it meets a system that has already selected for the right B cells. Antibody levels after a booster are consistently higher than after the first exposure, and a portion of those cells persist as memory cells.[5]
Sources disagree
How long protection lasts is contested. Estimates in these sources range from several months to over a year, measured differently in each.
By the end of this chapter you can read a vaccine efficacy number without being misled by it.
What the clinical trials showed
The registrational trials were randomised and placebo controlled, with tens of thousands of participants each. Reported efficacy against symptomatic disease was roughly 95% in the initial readouts, with confidence intervals stated alongside the point estimate.[6]
Efficacy is a relative measure: it compares infection rates between arms of the trial, not the chance that any individual falls ill. It is also measured against the variants circulating during the trial window, which is why later real world numbers differ without either figure being wrong.[7]
By the end of this chapter you can state what this technology still does not solve.
Limitations and open questions
Delivery remains the bottleneck. Only a small fraction of lipid nanoparticles escape the endosome successfully; the rest are broken down in lysosomes, which caps how much protein a given dose can produce.[1]
Cold chain requirements, reactogenicity after the second dose, and durability of protection are all active areas of work rather than settled questions.[4][5] A course that told you otherwise would be overstating what the sources support.
Where this course stops
Nothing here covers self amplifying mRNA or cancer vaccines. Both would be their own course.